DOWNEY, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Blum Holdings, Inc. (OTCQB: BLMH) (the “Company,” “Blüm,” “Blüm Holdings,” “we” or “us”), a California-based publicly traded holding company, is ...

Strategic Move Positions YD Bio Limited for Accelerated Innovation and Market ExpansionTrading of common stock and warrants of the new public company, YD Bio Limited, is expected to commence on the Na ...

The Online Gaming Bill 2025 hasn’t just silenced fantasy platforms—it’s shut down a decade-long ad engine powering agencies, production houses, and celebrity deals ...

After fielding multiple investor calls prompted by misleading August 28 Benzinga posts, the Company confirms no new S-1/A was ...

Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey ...

In July 2025, the first interim analysis results from the phase III clinical study of KN026 in combination with chemotherapy as second-line or above treatment of HER2-positive GC/GEJ were accepted by ...

Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey ...

- In March 2025, Everest announced that the U.S. FDA has cleared its IND application for EVM14, a TAA vaccine. EVM14 is Everest's first internally developed mRNA therapeutic vaccine to receive FDA IND ...